Schechter Investment Advisors LLC Purchases Shares of 2,602 DexCom, Inc. (NASDAQ:DXCM)

Schechter Investment Advisors LLC acquired a new position in DexCom, Inc. (NASDAQ:DXCM) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 2,602 shares of the medical device company’s stock, valued at approximately $202,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of DXCM. Versant Capital Management Inc acquired a new position in DexCom in the fourth quarter worth $25,000. Private Trust Co. NA boosted its stake in DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock worth $26,000 after purchasing an additional 245 shares in the last quarter. Heck Capital Advisors LLC acquired a new position in DexCom in the fourth quarter worth $38,000. SBI Securities Co. Ltd. acquired a new position in DexCom in the fourth quarter worth $49,000. Finally, Midwest Capital Advisors LLC acquired a new position in DexCom in the fourth quarter worth $54,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insider Buying and Selling at DexCom

In other DexCom news, CEO Kevin R. Sayer sold 33,359 shares of the stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $2,899,230.69. Following the completion of the sale, the chief executive officer now directly owns 319,037 shares in the company, valued at $27,727,505.67. This represents a 9.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Jacob Steven Leach sold 2,634 shares of the stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the sale, the chief operating officer now owns 268,644 shares of the company’s stock, valued at $23,347,850.04. This trade represents a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 38,083 shares of company stock valued at $3,309,794. 0.30% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

DXCM has been the topic of a number of recent analyst reports. Morgan Stanley boosted their price objective on DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research note on Friday, February 14th. Citigroup boosted their price objective on DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a research note on Tuesday. Baird R W raised DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Redburn Atlantic raised DexCom from a “neutral” rating to a “buy” rating and upped their price target for the company from $85.00 to $115.00 in a research note on Monday, February 3rd. Finally, Canaccord Genuity Group upped their price target on DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a research note on Friday, February 14th. Four research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $99.82.

DexCom Trading Down 3.0 %

NASDAQ:DXCM opened at $79.51 on Friday. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The business’s 50-day moving average price is $84.88 and its two-hundred day moving average price is $76.96. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $31.07 billion, a price-to-earnings ratio of 55.60, a PEG ratio of 2.30 and a beta of 1.14.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, equities analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.